Selected article for: "high RNA throughput sequencing and throughput sequencing"
Author: Szemiel, Agnieszka M.; Merits, Andres; Orton, Richard J.; MacLean, Oscar A.; Pinto, Rute Maria; Wickenhagen, Arthur; Lieber, Gauthier; Turnbull, Matthew L.; Wang, Sainan; Furnon, Wilhelm; Suarez, Nicolas M.; Mair, Daniel; da Silva Filipe, Ana; Willett, Brian J.; Wilson, Sam J.; Patel, Arvind H.; Thomson, Emma C.; Palmarini, Massimo; Kohl, Alain; Stewart, Meredith E.
Title: In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2
  • Cord-id: vuluc52g
  • Document date: 2021_9_17
    • ID: vuluc52g
    Snippet: Remdesivir (RDV), a broadly acting nucleoside analogue, is the only FDA approved small molecule antiviral for the treatment of COVID-19 patients. To date, there are no reports identifying SARS-CoV-2 RDV resistance in patients, animal models or in vitro. Here, we selected drug-resistant viral populations by serially passaging SARS-CoV-2 in vitro in the presence of RDV. Using high throughput sequencing, we identified a single mutation in RNA-dependent RNA polymerase (NSP12) at a residue conserved
    Document: Remdesivir (RDV), a broadly acting nucleoside analogue, is the only FDA approved small molecule antiviral for the treatment of COVID-19 patients. To date, there are no reports identifying SARS-CoV-2 RDV resistance in patients, animal models or in vitro. Here, we selected drug-resistant viral populations by serially passaging SARS-CoV-2 in vitro in the presence of RDV. Using high throughput sequencing, we identified a single mutation in RNA-dependent RNA polymerase (NSP12) at a residue conserved among all coronaviruses in two independently evolved populations displaying decreased RDV sensitivity. Introduction of the NSP12 E802D mutation into our SARS-CoV-2 reverse genetics backbone confirmed its role in decreasing RDV sensitivity in vitro. Substitution of E802 did not affect viral replication or activity of an alternate nucleoside analogue (EIDD2801) but did affect virus fitness in a competition assay. Analysis of the globally circulating SARS-CoV-2 variants (>800,000 sequences) showed no evidence of widespread transmission of RDV-resistant mutants. Surprisingly, we observed an excess of substitutions in spike at corresponding sites identified in the emerging SARS-CoV-2 variants of concern (i.e., H69, E484, N501, H655) indicating that they can arise in vitro in the absence of immune selection. The identification and characterisation of a drug resistant signature within the SARS-CoV-2 genome has implications for clinical management and virus surveillance.

    Search related documents:
    Co phrase search for related documents
    • accession number and acute respiratory syndrome: 1, 2, 3
    • acetic acid and active site: 1, 2
    • active cathepsin and acute respiratory syndrome: 1
    • active form and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active form and acute sars cov respiratory syndrome virus: 1, 2, 3, 4, 5
    • active form and additional information: 1, 2
    • active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and acute sars cov respiratory syndrome virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • active site and additional information: 1, 2
    • acute respiratory syndrome and adapt treatment: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and adaptation sars: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and additional information: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome virus and adapt treatment: 1
    • acute sars cov respiratory syndrome virus and adaptation sars: 1, 2, 3